🚨 New meta-analysis in RMD Open:
In pregnant women with antiphospholipid syndrome (APS), adding hydroxychloroquine (HCQ) to standard therapy was linked to:
✅ Higher live birth rates (OR 2.66)
✅ Lower obstetric complications (OR 0.19)
🍼 Well tolerated during pregnancy
🔗 https://t.co/8tT7qnrC98
#Rheumatology #APS #PregnancyJourney
PPIs are one of most commonly (and often inappropriately) prescribed drug classes out there. This is a “Must Read” state-of-the-art review paper on PPIs, covering indications, harms & a guide for deprescribing 🆕 💊⚠️
🔗 https://t.co/lYyY8ymkcr
H/T @drkeithsiau
As the #GCA landscape evolves, consistent terminology is essential for trials.
We developed a glossary of key signs/symptoms — a collaborative effort by an international task force.
📌 Part of the ACR/EULAR-supported #ResponseCriteria project.
🔗 https://t.co/otY2gcWEBH
Secukinumab fails in GCA phase 3 RCT. Novartis announced top-line results from the GCAptAIN study evaluating secukinumab in adults with newly diagnosed or relapsing GCA. In a steroid taper RCT, the endpoint was sustained remission at Wk 52 compared to placebo https://t.co/OElPntjNNu
#Autoimmune inner #ear disease (AIED) is a rare clinical entity (~ 1% of all cases of #hearing loss) characterized by a progressive fluctuating bilateral asymmetric sensorineural hearing loss that develops over several weeks to months. #Vestibular symptoms, #tinnitus and aural fullness are present in up to 50% of patients. AIED is defined as primary when the pathology is restricted to the ear. In up to a third of cases, AIED occurs in the context of a systemic autoimmune disease and is defined as secondary.
Due to the lack of specific diagnostic tests, both clinical suspicion and responsiveness to corticosteroids are the pillars for the diagnosis of autoimmune AIED. The evaluation of patients in whom this condition is suspected should include a detailed history and physical examination, an audiogram, an MRI and a limited laboratory workup to exclude secondary causes of hearing loss.
*From: Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the otology-rheumatology interface. Rheumatology (Oxford). 2013;52(5):780-789.
🔗https://t.co/L2WlCUGgS7
#WorldHearingDay #WorldHearingDay2025
Tweet 1:
🚀 The JAK-STAT Pathway – A Key Player in Cytokine Signaling!
Did you know that >40 receptors use this pathway? It’s critical for immune function, hematopoiesis, and inflammation!
Let’s break down JAKs, STATs, inhibitors & their clinical impact in a simple & engaging way! 🧵👇
#JAKSTAT #Immunology #Rheumatology #Sullysrounds #Trump #MedX #MedTwitter
🚨Landmark trial: First anti-CD20ab, Obinutuzumab with +ve Phase 3 trial in #lupus nephritis is out 👏🙌🏻. OBI + MMF + GC was superior than Placebo + MMF + GC at WK76; complete renal response (uPCR<0.5, eGFR =>85% of baseline, no rescue); 46.4% vs 33.1%.
https://t.co/sflPccqQCs
Pain is often ignored in myositis - comes from active disease, muscle damage & pain syndromes. Pain is common in myositis and associated with disease activity, so treating disease activity is imp. https://t.co/PexznSvy1E
🩺 Vascular inflammation persists in GCA patients despite prolonged treatment with GCs and TCZ
🔬 38.5% of patients still showed inflammation in repeated temporal artery biopsies after TCZ
🖼️ PET/CT and ultrasound also revealed ongoing activity
🔑 https://t.co/T9H2DyCVSH
🤰 “Fertility in women with RA is nearly equal to the general population when treated according to a treat-to-target approach aimed at remission of disease"
More from Dr. Radboud Dolhain @ErasmusMC at #ACR24 ⬇️
https://t.co/t6x9grjo0M
How long before starting MTX should pts receive PCV13 vaccine?
➡️In RA, PCV13 vaccine given 1 month before starting MTX led to significantly higher immunological response at 1 month compared to pts vaccinated on MTX
⏩Vaccinate pts before starting MTX
Ab2676 #ACR24@RheumNow
PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE
Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts
1 MI & 1 death from infection over 213 pts
Encouraging for sure! Second phase 3 being launched
#ACR24@RheumNow Abstr#L16 #ACRbest